Tenaya Therapeutics Q3 EPS $(0.39) Beats $(0.47) Estimate
Portfolio Pulse from Benzinga Newsdesk
Tenaya Therapeutics reported Q3 losses of $(0.39) per share, beating the analyst consensus estimate of $(0.47) by 17.02%. This is a 47.3% increase over losses of $(0.74) per share from the same period last year.
November 08, 2023 | 10:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tenaya Therapeutics' Q3 losses were less than expected, which could be seen as a positive sign by investors.
Tenaya Therapeutics reported lower than expected losses for Q3, which is generally seen as a positive sign by investors. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100